Animal study · mice
Ac-SDKP taken by mouth eased kidney scarring in diabetic mice
Checked against the paper Animal studyPublished by PepVault
The takeaway
This paper adds mouse evidence that oral Ac-SDKP, alone or with imidapril, reduced kidney scarring in diabetic models. It is an animal finding, not proof of benefit in people.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2016
- Journal
- Biomed Res Int
What they tested
The team tested whether Ac-SDKP given by mouth, alone or with the ACE inhibitor imidapril, could treat kidney scarring (fibrosis) in diabetic mice.
How the study was done
A mouse study using models of diabetic kidney disease: CD-1 mice made type 1 diabetic with streptozotocin, and db/db mice with type 2 diabetes. Treated groups got imidapril, oral Ac-SDKP, or both together.

What they found
In both diabetic mouse models, every treatment raised Ac-SDKP levels in urine, and the combination group had significantly higher levels than the other groups. Oral Ac-SDKP, alone or with imidapril, lessened glomerulosclerosis (scarring of the kidney's filtering units) and tubulointerstitial fibrosis (scarring in the tissue around the kidney tubules). Plasma cystatin C, a blood marker of kidney function, was raised in the diabetic mice and was restored by every treatment. Kidney levels of miR-29 and let-7, small RNAs the team describes as anti-scarring, were low in the diabetic mice and came back to normal or higher, especially with the combination.
What it doesn’t show
This was done in mice, so it is not a result in people. The study did not test oral Ac-SDKP in humans with diabetic kidney disease.
The paper
Nitta et al. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen. Biomed Res Int. 2016.
The compound
More studies on Ac-SDKP
- Ac-SDKP: blood levels fell after kidney transplant in 14 patientsClinical trial · people · 2014
- Every study on Ac-SDKP
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.